Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole

Trazpiroben, a dopamine D(2)/D(3) receptor antagonist under development to treat gastroparesis, displays decreasing solubility with increasing pH. This single‐sequence, open‐label, two‐period, crossover study evaluated the effect of esomeprazole, a proton pump inhibitor that raises gastric pH, on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur Mukker, Jatinder, Dukes, George, Wang, Lisi, Huh, Susanna, Khudyakov, Polyna, Nishihara, Mitsuhiro, Chen, Chunlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099131/
https://www.ncbi.nlm.nih.gov/pubmed/35218604
http://dx.doi.org/10.1111/cts.13248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099131/
https://www.ncbi.nlm.nih.gov/pubmed/35218604
http://dx.doi.org/10.1111/cts.13248

Ejemplares similares